Abstract Details

Title Characteristics and Treatment Response to OnabotulinumtoxinA of Patients From CD-PROBE With Anterocollis and Retrocollis

Topic Movement Disorders

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 5-005

Objective To describes baseline characteristics and treatment response of these cervical dystonia (CD) subtypes.

Background CD-PROBE included patients with anterocollis (AC) and retrocollis (RC) treated with onabotulinumtoxinA (onabotA).

Design/Methods CD PROBE was an observational, prospective study designed to identify real-world outcomes in patients with CD after onabotA treatment; patients from 82 US sites with CD diagnosis who were candidates for onabotA therapy, new to treatment, or not previously treated in a clinical trial in ≥16 weeks, and completed 3 onabotA treatments. Treatment benefit was measured using the Patient’s Global Impression of Change (PGI-C), Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Cervical Dystonia Impact Profile (CDIP-58), Clinician’s Global Impression of Change (CGI-C), and physician assessments of CD severity.

Results Patients with AC (n=59) and RC (n=55) were older and more disabled, with a shorter time to diagnosis and treatment, than patients with laterocollis (LC) or torticollis (TC). From PGI-C responses, 58.4% of RC vs 47.8% of AC patients reported being much/very much improved by onabotA post-injection 3 (final visit). CGI-C responses similarly improved over this timeframe; 82.6% of RC and 60.9% of AC patients reporting much/very much improved. The mean total TWSTRS score decreased for AC and RC patients from injection 1 (46 [AC]; 40 [RC]) to final visit (36 [AC]; 32 [RC]); CDIP-58 scores also decreased over time. The proportion of patients with physician-assessed severe CD decreased from injection 1 (28.8% [AC]; 21.8% [RC]) to final visit (21.7% [AC]; 4.3% [RC]); most patients shifted to lower symptom severity. OnabotA dose generally increased per visit, with AC patients having lowest doses (153.5–195.4U) and RC patients the highest (184.0–213.4U). Adverse event of dysphagia reported in 4 AC and 7 RC patients. No new safety signals were identified.

Conclusions CD PROBE data indicates real-world treatment with onabotA relieves CD symptoms in patients with anterocollis and retrocollis.

Authors/Disclosures
Marjan Sadeghi, PharmD (Abbvie) PRESENTER	Dr. Sadeghi has received personal compensation for serving as an employee of AbbVie. Dr. Sadeghi has stock in Abbvie.
Khashayar Dashtipour, MD, PhD	Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine . Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for teva. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for abbvie. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for acadia. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for kyowa kirin . Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for amneal . Dr. Dashtipour has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for neurocrine . Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for teva. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for abbvie. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for kyowa Kirin . Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ipsen. Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for amneal . Dr. Dashtipour has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for acorda. The institution of Dr. Dashtipour has received research support from Abbvie. The institution of Dr. Dashtipour has received research support from ipsen. The institution of Dr. Dashtipour has received research support from amneal.
Joseph Jankovic, MD, FAAN (Baylor College of Medicine)	Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance, Allergan. The institution of Dr. Jankovic has received research support from Baylor College of Medicine. Dr. Jankovic has received research support from Abbvie. The institution of Dr. Jankovic has received research support from Abbvie.
P. D. Charles, MD, FAAN (Vanderbilt University Medical Center)	Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceraxis. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspen Neuroscience. Dr. Charles has stock in Arena Therapeutics. The institution of Dr. Charles has received research support from Pharma 2 B. The institution of Dr. Charles has received research support from Intec. The institution of Dr. Charles has received research support from Merz. The institution of Dr. Charles has received research support from Novartis. The institution of Dr. Charles has received research support from Aeon. The institution of Dr. Charles has received research support from Impax. The institution of Dr. Charles has received research support from AskBio. The institution of Dr. Charles has received research support from BlueRock. The institution of Dr. Charles has received research support from AbbVie. The institution of Dr. Charles has received research support from Ipsen.
Shyamal Mehta, MD, PhD, FAAN (Mayo Clinic, Arizona)	Dr. Mehta has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Adamas Pharma. Dr. Mehta has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Mehta has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CNS Ratings.
	No disclosure on file

��ɫ��

��ɫ��